Global Research for Medical Progress for the Benefit of the Patient

Bayer is the only global company simultaneously researching improvements in human, animal and plant health. Systematic and intensive collaboration among researchers beyond their original specialization is providing new impetus. From world-renowned pharmaceutical products to high-tech platforms, from innovative diagnostics technologies to veterinary medicines – Bayer lives an innovation culture across national borders and areas of research.

Research Areas at Bayer

 

Pharmaceuticals

Research - Pharmaceuticals Zoom image

Dr. Jürgen Klar and Dr. Michael Böttger (left to right) from Bayer in Wuppertal evaluate images showing the condition of the blood vessels at the back of the eye.

Drug discovery in the Pharmaceuticals division focuses on the areas of cardiology, oncology, ophthalmology, hematology radiology and gynecology.

 

 

Riociguat

Adempas™ (active ingredient: riociguat) is the first member of a new class of vasodilating agents known as soluble guanylate cyclase (sGC) modulators. Administered in tablet form, riociguat is currently being investigated as a new, specific approach for the treatment of various forms of pulmonary hypertension. more

 


Regorafenib

Stivarga™ (active ingredient: regorafenib) is an oral multikinase inhibitor. It inhibits various signal pathways that are responsible for tumor growth. more

 

Ra-223-Dichlorid

Xofigo™ (active ingredient: radium-223 dichloride) is approved in the E.U. and the United States for the treatment of adult patients with castration-resistant prostate cancer (CRPC) with symptomatic bone metastases but no known visceral metastases. more

 

Afilibercept

Eylea™ (active ingredient: aflibercept) is our joint developmental project with Regeneron Pharmaceuticals, Inc., United States. Aflibercept blocks the natural growth factor VEGF (vascular endothelial growth factor), thus preventing the abnormal formation of new blood vessels that tend to leak blood. The medication is administered directly into the eye. Regeneron Pharmaceuticals, Inc. holds exclusive rights to the product in the United States, while in other countries it is marketed by Bayer. more

 

Sorafenib

Xarelto™ (active ingredient: rivaroxaban) has been approved for more indications in the area of venous and arterial thromboembolism than any of the other new oral anticoagulants. Xarelto™ is approved in more than 125 countries worldwide across all indications, its approval status varying from country to country. more

 

Rivaroxaban

Xarelto™ (active ingredient: rivaroxaban) has been approved for more indications in the area of venous and arterial thromboembolism than any of the other new oral anticoagulants. Xarelto™ is approved in more than 125 countries worldwide across all indications, its approval status varying from country to country. more

 

Radiology

The aim of our research and development activities in the area of contrast agents and medical equipment (Radiology business unit) is to steadily improve our contrast agents and our contrast injection systems in order to build on our leadership position. more

 

 


 

Consumer Health

Research - Consumer Health Zoom image

Andreas Werner (left) and Francesco Lo Grande clean and monitor the stirring rods of an ointment mixer for the production of Bepanthen™ wound and healing ointment.

In our Consumer Health Division, research and development activities at the product development centers in Morristown, New Jersey and Memphis, Tennessee, United States, and Gaillard, France, focus on developing non-prescription medicines, medical skincare products, foot care products, sunscreens and nutritional supplements to market maturity. Aligned to end consumers, our development strategies are geared toward expanding and improving our brand portfolio through new products and delivery forms. We also work to achieve reclassification of current prescription medicines as OTC products. We introduced a number of new product line expansions to various markets in 2014. They included new delivery forms and uses for existing brands such as Canesten™, Bepanthen™/Bepanthol™, Coppertone™ and Dr. Scholl’s™.

 


 

Animal Health

Research - Animal Health Zoom image

Lab assistant Carolin Geier examinating round worms in a lab in Monheim.

In our Animal Health business unit, we focus our research and development activities on antiparasitics, antibiotics and medicines to treat non-infectious disorders. We operate R&D centers in Germany, the United States, New Zealand and Brazil. Our central research activities are conducted in Monheim, Germany. We reinforce the business by continually identifying further product development candidates through our existing collaborations.